Ruifu Chemical is the leading manufacturer of 3,5-Bis(trifluoromethyl)phenylacetic Acid (CAS: 85068-33-3) with high quality, intermediate of Netupitant (CAS: 290297-26-6). Ruifu Chemical can provide worldwide delivery, competitive price, excellent service, small and bulk quantities available. Please contact: alvin@ruifuchem.com
| Chemical Name | 3,5-Bis(trifluoromethyl)phenylacetic Acid |
| Synonyms | 2-[3,5-Di(trifluoromethyl)phenyl]acetic Acid |
| CAS Number | 85068-33-3 |
| Stock Status | In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula | C10H6F6O2 |
| Molecular Weight | 272.14 |
| Melting Point | 121.0~130.0℃ (lit.) |
| Solubility Methanol | Soluble 25mg/mL, Clear, Colorless |
| COA & MSDS | Available |
| Place of Origin | Shanghai, China |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White or Off-White Crystalline Powder |
| Purity / Analysis Method | ≥99.0% (HPLC) |
| Melting Point | 121.0~130.0℃ |
| Loss on Drying | ≤1.00% |
| Total Impurities | ≤1.00% |
| Fluorine NMR Spectrum | Conforms to Structure |
| Infrared Spectrum | Conforms to Structure |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Netupitant (CAS: 290297-26-6) |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.
Hazard Symbols Xi - Irritant
Risk Codes 36/37/38 - Irritating to eyes, respiratory system and skin.
Safety Description S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S36 - Wear suitable protective clothing.
S37/39 - Wear suitable gloves and eye/face protection
WGK Germany 3
HS Code 2916399090
Hazard Class IRRITANT
3,5-Bis(trifluoromethyl)phenylacetic Acid (CAS: 85068-33-3) is mainly used in pharmaceutical industry as a pharmaceutical intermediate. 3,5-Bis(trifluoromethyl)phenylacetic Acid can be used as an intermediate of Netupitant (CAS: 290297-26-6), chemical name 2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamide. Netupitant, originally developed by Helsinn Healthcare and later licensed to Eisai, Inc., was approved in the USA in October 2014 for the treatment of chemotherapy-induced nausea and emesis.